{"filing":{"accession_number":"0001935979-26-000053","cik":"0001935979","ticker":"BHVN","company_name":"Biohaven Ltd.","form":"8-K","filing_date":"2026-07-09","report_date":null,"primary_document":"bhvn-20260709.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1935979/000193597926000053/bhvn-20260709.htm"},"events":[{"id":16903,"run_id":15127,"accession_number":"0001935979-26-000053","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.72,"summary":"The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-07-09","form":"8-K","submitted_at":null,"items":[{"id":15143,"accession_number":"0001935979-26-000053","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:51:45.481344+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15143,"accession_number":"0001935979-26-000053","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.72,"reasoning":"The disclosure centers on two executive transitions: David Pirman's promotion to Executive Vice President and Head of Discovery (a clear appointment to a senior role), and Bruce Car's transition from Chief Scientific Officer to Chief Innovation Officer (a role change with reduced compensation). While Car's departure from the CSO role is mentioned, the filing emphasizes the new appointments and organizational restructuring rather than focusing on departures. The promotion of Pirman to lead the internal drug-discovery organization and Car's continued service as an executive officer in a newly created role constitute material executive appointments that would affect investor assessment of the company's scientific leadership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-10T10:51:45.481344+00:00","company_name":"Biohaven Ltd.","ticker":"BHVN","filing_date":"2026-07-09"}]}